Home LiteratureArticle Details
PMID: 7869034 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line.

The Journal of experimental medicine ·Vol. 181 ·No. 3 ·1995-03-01 ·Pages 1169-77

Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE

Abstract

Treatment of immature murine B lymphocytes with an antiserum against their surface immunoglobulin (sIg)M results in cell death via apoptosis. The WEHI 231 B cell line (IgM, kappa) has been used extensively as a model for this anti-Ig receptor-mediated apoptosis. Anti-sIg treatment of WEHI 231 cells causes an early, transient increase in the levels of c-myc messenger RNA and gene transcription, followed by a rapid decline below control values. Given the evidence for a role of the c-myc gene in promoting apoptosis, we have characterized the nature and kinetics of changes in the binding of Rel-related factors, which modulate c-myc promoter activity. In exponentially growing WEHI 231 cells, multiple Rel-related binding activities were detectable. The major binding species was identified as p50/c-Rel heterodimers; only minor amounts of nuclear factor kappa B (NF-kappa B) (p50/p65) were detectable. Cotransfection of an inhibitor of NF-kappa B (I kappa B)-alpha expression vector reduced c-myc-promoter/upstream/exon1-CAT reporter construct activity, indicating the role of Rel factor binding in c-myc basal expression in these cells. Treatment with anti-sIg resulted in a rapid transient increase in the rate of c-myc gene transcription and in the binding of Rel factors. At later times, formation of p50 homodimer complexes occurred. In cotransfection analysis, p65 and c-Rel expression potently and modestly transactivated the c-myc promoter, respectively, whereas, overexpression of the p50 subunit caused a significant drop in its activity. The role of activation of Rel-family binding was demonstrated directly upon addition of the antioxidant pyrrolidinedithiocarbamate, which inhibited the anti-sIg-mediated activation of the endogenous c-myc gene. Similarly, induction after anti-sIg treatment of a transfected c-myc promoter was abrogated upon cotransfection of an I kappa B-alpha expression vector. These results implicate the Rel-family in Ig receptor-mediated signals controlling the activation of c-myc gene transcription in WEHI 231 cells, and suggest a role for this family in apoptosis of this line, which is mediated through a c-myc signaling pathway.

Related Genes
c-myc
MeSH Terms
Animals Apoptosis Cells, Cultured Gene Expression Regulation Genes, myc Lymphoma, B-Cell/genetics,pathology Mice NF-kappa B/metabolism Promoter Regions, Genetic Proto-Oncogene Proteins/analysis,physiology Proto-Oncogene Proteins c-rel Receptors, Antigen, B-Cell/physiology Receptors, Immunologic/physiology Transcription, Genetic
Chemicals
NF-kappa B Proto-Oncogene Proteins Proto-Oncogene Proteins c-rel Receptors, Antigen, B-Cell Receptors, Immunologic
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Lee H
Department of Biochemistry, Boston University Medical School, Massachusetts 02118.
Arsura M
Wu M
Duyao M
Buckler A J
Sonenshein G E
References (43)
43 references, click to expand
  1. DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide.
    Cell. 1991 Mar 8;64(5):961-9 PMID: 2001591
  2. Transcriptional and posttranscriptional control of c-myc gene expression in WEHI 231 cells.
    Mol Cell Biol. 1986 Nov;6(11):4112-6 PMID: 3796600
  3. NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit.
    EMBO J. 1991 Jul;10(7):1817-25 PMID: 2050119
  4. Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65.
    Nature. 1991 Aug 22;352(6337):733-6 PMID: 1876189
  5. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.
    Oncogene. 1991 Oct;6(10):1915-22 PMID: 1923514
  6. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B.
    EMBO J. 1991 Dec;10(12):3805-17 PMID: 1935902
  7. Changes in phosphorylation of myc oncogene and RB antioncogene protein products during growth arrest of the murine lymphoma WEHI 231 cell line.
    Oncogene. 1991 Nov;6(11):1965-71 PMID: 1719463
  8. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.
    Cell. 1991 Dec 20;67(6):1075-87 PMID: 1760839
  9. Studies of surface immunoglobulin-dependent B cell activation.
    Immunol Res. 1988;7(2):136-51 PMID: 3292672
  10. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures.
    Nature. 1989 Jan 12;337(6203):181-4 PMID: 2521375
  11. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.
    Cell. 1989 Jul 28;58(2):227-9 PMID: 2665943
  12. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter.
    Proc Natl Acad Sci U S A. 1990 Jun;87(12):4727-31 PMID: 2191300
  13. Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells.
    Eur J Immunol. 1990 Jun;20(6):1405-7 PMID: 2369921
  14. The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product.
    Cell. 1990 Sep 7;62(5):1007-18 PMID: 2203531
  15. Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal.
    Cell. 1990 Sep 7;62(5):1019-29 PMID: 2203532
  16. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas.
    Eur J Immunol. 1990 Aug;20(8):1685-90 PMID: 2209683
  17. Inducible nuclear expression of NF-kappa B in primary B cells stimulated through the surface Ig receptor.
    J Immunol. 1991 Mar 1;146(5):1685-91 PMID: 1993849
  18. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.
    Mol Cell Biol. 1992 Feb;12(2):674-84 PMID: 1732739
  19. A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site.
    Mol Cell Biol. 1992 Feb;12(2):685-95 PMID: 1531086
  20. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression.
    Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1875-9 PMID: 1542686
  21. Induction of apoptosis in fibroblasts by c-myc protein.
    Cell. 1992 Apr 3;69(1):119-28 PMID: 1555236
  22. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
    J Exp Med. 1992 May 1;175(5):1181-94 PMID: 1314883
  23. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.
    Science. 1992 Jul 10;257(5067):212-4 PMID: 1378649
  24. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B.
    J Biol Chem. 1992 Aug 15;267(23):16288-91 PMID: 1644814
  25. NF-kappa B-like factors mediate interleukin 1 induction of c-myc gene transcription in fibroblasts.
    J Exp Med. 1992 Sep 1;176(3):787-92 PMID: 1512542
  26. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation.
    Mol Cell Biol. 1992 Oct;12(10):4412-21 PMID: 1406630
  27. A novel NF-kappa B element within exon 1 of the murine c-myc gene.
    Oncogene. 1992 Dec;7(12):2447-53 PMID: 1461649
  28. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites.
    EMBO J. 1993 Oct;12(10):3893-901 PMID: 8404857
  29. In vivo control of NF-kappa B activation by I kappa B alpha.
    EMBO J. 1993 Dec;12(12):4685-95 PMID: 8223478
  30. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro.
    Cell. 1993 Dec 3;75(5):899-912 PMID: 8252626
  31. Lymphoma models for B cell activation and tolerance. X. Anti-mu-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc.
    J Exp Med. 1994 Jan 1;179(1):221-8 PMID: 8270867
  32. Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors.
    Mol Cell Biol. 1994 Feb;14(2):1039-44 PMID: 8289784
  33. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines.
    Mol Cell Biol. 1994 May;14(5):3276-82 PMID: 8164680
  34. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation.
    Mol Cell Biol. 1994 Aug;14(8):5349-59 PMID: 8035813
  35. Functional subsets of murine and human B lymphocyte cell lines.
    Immunol Rev. 1979;48:107-21 PMID: 94896
  36. The regulation of growth and differentiation of a murine B cell lymphoma. II. The inhibition of WEHI 231 by anti-immunoglobulin antibodies.
    J Immunol. 1981 Jun;126(6):2466-9 PMID: 6785356
  37. Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas.
    Nature. 1983 Jun 2-8;303(5916):401-6 PMID: 6304522
  38. Cell cycle regulation of mouse H3 histone mRNA metabolism.
    Mol Cell Biol. 1984 Jan;4(1):123-32 PMID: 6583492
  39. A protein binds to a satellite DNA repeat at three specific sites that would be brought into mutual proximity by DNA folding in the nucleosome.
    Cell. 1984 Jul;37(3):889-901 PMID: 6540146
  40. Specific regulation of c-myc oncogene expression in a murine B-cell lymphoma.
    Proc Natl Acad Sci U S A. 1984 Sep;81(17):5546-50 PMID: 6206500
  41. Multiple nuclear factors interact with the immunoglobulin enhancer sequences.
    Cell. 1986 Aug 29;46(5):705-16 PMID: 3091258
  42. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.
    Cell. 1986 Dec 26;47(6):921-8 PMID: 3096580
  43. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits.
    Biochim Biophys Acta. 1991 Apr 16;1072(1):63-80 PMID: 2018779
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
DOI
10.1084/jem.181.3.1169
Published
1995-03-01
Pages
1169-77
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2191927
Subset
IM
Grants
NIA NIH HHS · AG-00115 · United States
NCI NIH HHS · CA36355 · United States
External Links
PubMed source DOI: 10.1084/jem.181.3.1169 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2